ETNB 89bio Inc
Price (delayed)
$7.19
Market cap
$1.05B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.51
Enterprise value
$961.12M
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is
Highlights
89bio's quick ratio has decreased by 38% YoY but it has increased by 12% from the previous quarter
The equity is down by 25% year-on-year but it is up by 6% since the previous quarter
The company's net income has shrunk by 158% YoY and by 27% QoQ
ETNB's EPS has dropped by 76% year-on-year and by 21% since the previous quarter
Key stats
What are the main financial stats of ETNB
Market
Valuations
Earnings
Shares outstanding
145.98M
Market cap
$1.05B
Enterprise value
$961.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.9
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$384.66M
Net income
-$367.08M
EBIT
-$361.1M
EBITDA
-$360.34M
Free cash flow
-$367.84M
Per share
Balance sheet
Liquidity
EPS
-$3.51
EPS diluted
-$3.51
Free cash flow per share
-$3.51
Book value per share
$3.78
Revenue per share
$0
TBVPS
$4.57
Total assets
$478.69M
Total liabilities
$77.9M
Debt
$37.55M
Equity
$400.79M
Working capital
$440.32M
Debt to equity
0.09
Current ratio
13.19
Quick ratio
12.18
Net debt/EBITDA
0.25
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-70%
Return on equity
-81.4%
Return on invested capital
-101.4%
Return on capital employed
-81.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ETNB stock price
How has the 89bio stock price performed over time
Intraday
5.81%
1 week
-10.35%
1 month
-22.1%
1 year
-32.04%
YTD
-8.06%
QTD
-1.1%
Financial performance
How have 89bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$384.66M
Net income
-$367.08M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 158% YoY and by 27% QoQ
The company's operating income has shrunk by 154% YoY and by 27% QoQ
Growth
What is 89bio's growth rate over time
Valuation
What is 89bio stock price valuation
P/E
N/A
P/B
1.9
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ETNB's EPS has dropped by 76% year-on-year and by 21% since the previous quarter
The equity is down by 25% year-on-year but it is up by 6% since the previous quarter
The stock's price to book (P/B) is 18% less than its 5-year quarterly average of 2.2 and 10% less than its last 4 quarters average of 2.0
Efficiency
How efficient is 89bio business performance
89bio's return on equity has shrunk by 163% YoY and by 37% QoQ
ETNB's return on assets has dropped by 152% year-on-year and by 34% since the previous quarter
The ROIC has plunged by 66% YoY and by 22% from the previous quarter
Dividends
What is ETNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ETNB.
Financial health
How did 89bio financials performed over time
89bio's quick ratio has decreased by 38% YoY but it has increased by 12% from the previous quarter
ETNB's current ratio is down by 34% year-on-year but it is up by 13% since the previous quarter
89bio's debt is 91% lower than its equity
ETNB's debt to equity has soared by 80% YoY but it is down by 10% from the previous quarter
89bio's debt has increased by 39% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.